276 related articles for article (PubMed ID: 36255428)
1. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
Dusetzina SB; Huskamp HA; Qin X; Keating NL
JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
3. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
4. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage.
McWilliams JM; Zaslavsky AM; Huskamp HA
JAMA; 2011 Jul; 306(4):402-9. PubMed ID: 21791689
[TBL] [Abstract][Full Text] [Related]
5. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
6. Trends in Low-Value Health Service Use and Spending in the US Medicare Fee-for-Service Program, 2014-2018.
Mafi JN; Reid RO; Baseman LH; Hickey S; Totten M; Agniel D; Fendrick AM; Sarkisian C; Damberg CL
JAMA Netw Open; 2021 Feb; 4(2):e2037328. PubMed ID: 33591365
[TBL] [Abstract][Full Text] [Related]
7. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
[TBL] [Abstract][Full Text] [Related]
8. Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013.
Krumholz HM; Nuti SV; Downing NS; Normand SL; Wang Y
JAMA; 2015 Jul; 314(4):355-65. PubMed ID: 26219053
[TBL] [Abstract][Full Text] [Related]
9. Sources of regional variation in Medicare Part D drug spending.
Donohue JM; Morden NE; Gellad WF; Bynum JP; Zhou W; Hanlon JT; Skinner J
N Engl J Med; 2012 Feb; 366(6):530-8. PubMed ID: 22316446
[TBL] [Abstract][Full Text] [Related]
10. The effect of Medicare Part D on drug and medical spending.
Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
Park T; Jung J
J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Effects of Pioneer Accountable Care Organizations on Medicare Part D Drug Spending and Utilization.
Zhang Y; Caines KJ; Powers CA
Med Care; 2017 May; 55(5):470-475. PubMed ID: 28060052
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
14. Association Between Medicare Accountable Care Organization Implementation and Spending Among Clinically Vulnerable Beneficiaries.
Colla CH; Lewis VA; Kao LS; O'Malley AJ; Chang CH; Fisher ES
JAMA Intern Med; 2016 Aug; 176(8):1167-75. PubMed ID: 27322485
[TBL] [Abstract][Full Text] [Related]
15. Associations of Intensive Lifestyle Intervention in Type 2 Diabetes With Health Care Use, Spending, and Disability: An Ancillary Study of the Look AHEAD Study.
Huckfeldt PJ; Frenier C; Pajewski NM; Espeland M; Peters A; Casanova R; Pi-Sunyer X; Cheskin L; Goldman DP
JAMA Netw Open; 2020 Nov; 3(11):e2025488. PubMed ID: 33231638
[TBL] [Abstract][Full Text] [Related]
16. Association of Pioneer Accountable Care Organizations vs traditional Medicare fee for service with spending, utilization, and patient experience.
Nyweide DJ; Lee W; Cuerdon TT; Pham HH; Cox M; Rajkumar R; Conway PH
JAMA; 2015 Jun; 313(21):2152-61. PubMed ID: 25938875
[TBL] [Abstract][Full Text] [Related]
17. Changes in health care spending and quality for Medicare beneficiaries associated with a commercial ACO contract.
McWilliams JM; Landon BE; Chernew ME
JAMA; 2013 Aug; 310(8):829-36. PubMed ID: 23982369
[TBL] [Abstract][Full Text] [Related]
18. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
19. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
[TBL] [Abstract][Full Text] [Related]
20. Continuity of Care and Health Care Utilization in Older Adults With Dementia in Fee-for-Service Medicare.
Amjad H; Carmichael D; Austin AM; Chang CH; Bynum JP
JAMA Intern Med; 2016 Sep; 176(9):1371-8. PubMed ID: 27454945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
